Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 21Completed 4Terminated 2Not yet recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Advanced ER+, HER2-Negative Breast Cancer 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 183Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 93Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × elacestrant × Breast × Clear all
NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

NCT04797728 2022-10-26

ELIPSE

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed
23 enrolled
Breast

Breast Neoplasms

NCT02338349 2022-08-18

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
57 enrolled
Breast

Advanced ER+, HER2-Negative Breast Cancer

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡